삼성바이오로직스

207940KOSPI기초 의약물질 제조업

49.1 / 100

Reference Date: 2026-07-24

Financial Score15.5 / 40

News Sentiment17.6 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung BioLogics is a global CDMO (Contract Development and Manufacturing Organization) providing biopharmaceutical contract manufacturing and development services. In 2025, it restructured into a pure-play CDMO business by spinning off Samsung Epics Holdings. The company generates significant revenue from Europe and the U.S. and is expanding into next-generation biopharmaceuticals such as mRNA, ADC, and cell/gene therapies.

Number of Employees

10,910people

Average Salary

114.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

35.78Industry Average 25.443.0Point

Higher than industry avg (caution)

PBR

8.57Industry Average 1.260.0Point

6.8x industry avg (risky)

ROE

19.44Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

14.45Industry Average 6.620.0Point

2.2x industry avg (risky)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲37.6% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 13.0% (improving, 3yr)

Detailed News Sentiment

68 totalPositive 32Neutral 21Negative 15Average Sentiment Score 70.4

Neutral
[미리보는 이데일리 신문] 보유세 강화…초고가·다주택자는 더 올린...
Positive
매출 30% 뛴 삼성바이오… 올해 목표 성장률 달성 '청신호'
삼성바이오로직스의 분기 매출이 최대 기록을 세우며 목표 성장률 달성에 긍정적 신호를 보냈다.
Positive
삼성바이오, 6개 분기 연속 영업이익률 40%대
삼성바이오로직스가 6분기 연속으로 높은 영업이익률을 기록하며 지속적인 성장을 보여주고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 1,379,000Won52-week high 1,965,00052-week low 1,273,000

1-month return3.0Point

1m -0.43% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-07-23
Neutral주요사항보고서(타법인주식및출자증권양수결정)2026-07-20
Neutral결산실적공시예고(안내공시)2026-07-09
Neutral최대주주등소유주식변동신고서2026-07-06